Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine.

Molecular diagnosis & therapy - 1 Apr 2012

Staeker Julia, Leucht Stefan, Steimer Werner

Abstract excerpt

BACKGROUND AND OBJECTIVE: Weight gain is a common problem of treatment with atypical antipsychotics. However, the dimension of body weight change differs interindividually, and various genetic factors are considered to be associated with this effect. Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala polymorphism and its reported relationship to type 2 diabetes susceptibility and body mass...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Benzodiazepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Body Mass Index

Share to Clozapine

Share to Mental Disorders

Share to Olanzapine

Share to PPAR gamma

Share to Weight Gain

Source

Identifiers

PMID: 22413765
DOI: 10.2165/11599880-000000000-00000

Genes

PPARG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine.PMID 22413765Read ↗

The Association of Olanzapine-Induced Weight Gain with Peroxisome Proliferator–Activated Receptor-γ2 Pro12Ala Polymorphism in Patients with SchizophreniaSemantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Semantic proximity Read ↗

No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances.Semantic proximity Read ↗

Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical ReviewSemantic proximity Read ↗

TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.Semantic proximity Read ↗

Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia.Semantic proximity Read ↗

Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain.Semantic proximity Read ↗

Genetic Correlates of Olanzapine-Induced Weight Gain in Schizophrenia Subjects from North India: Role of Metabolic Pathway GenesSemantic proximity Read ↗

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.Semantic proximity Read ↗

Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain.Semantic proximity Read ↗

Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.